Gıancarlo Comı

Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress

Assessing disease progression and treatment response in progressive multiple sclerosis

The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care – updates at the 2023 plenary event

Locus for severity implicates CNS resilience in progression of multiple sclerosis

Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury

Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force

Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study

Multiple sclerosis progression: time for a new mechanism-driven framework

Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement–the Mobilise-D study protocol

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1-1.Virtual)

2233 Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 DMTs deleterious for COVID-19 severity but interferons not protective among people with MS

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies

Associations of DMT therapies with COVID-19 severity in multiple sclerosis

First results of the COVID-19 in ms global data sharing initiative suggest anti-CD20 dmts are associated with worse covid-19 outcomes

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Role of B Cells in Multiple Sclerosis and Related Disorders

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study

Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study

Multiple Sclerosis Data Alliance – A global multi-stakeholder collaboration to scale-up real world data research

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Engaging across dimensions of diversity: A cross-national perspective on mHealth tools for managing relapsing remitting and progressive multiple sclerosis

Thrombolysis in elderly stroke patients in Italy (TESPI) trial and updated meta-analysis of randomized controlled trials